Synapse - Lorenzo Falchi

Results (108)

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma

Research Letter

Uppal, M.; Joseph, A.; Drill, E.; Hamlin, P.; Falchi, L.; Noy, A.; Owens, C.; Epstein-Peterson, Z. D.; Salles, G.; Zelenetz, A. D.; more...
British Journal of Haematology (2025)

Fulltext@MSK | Save

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma

Research Letter

Falchi, L.; Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
Haematologica (2025)

Fulltext@MSK | Save

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience

Journal Article

Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
Haematologica (2025)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Journal Article

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
Blood (2025)

Fulltext@MSK | Save

Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes

Meeting Abstract

Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Impact of broad-spectrum antibiotic exposure on CAR-T therapy outcomes in B-cell lymphoma: A multicenter international study

Meeting Abstract

Shouval, R.; Fei, T.; Gabrielli, G.; Smith, N. G.; Ghilardi, G.; Slingerland, J.; Peled, J. U.; Taur, Y.; Nasta, S. D.; Luna, A.; more...
Blood (2024)

Fulltext@MSK | Save

Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas

Meeting Abstract

Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
Neuro-Oncology (2024)

Fulltext@MSK | Save

Patterns of intracranial response and relapse after CNS-directed radiotherapy (CNS-RT) for patients with chemorefractory or progressive secondary CNS lymphoma (SCNSL)

Meeting Abstract

Cederquist, G.; Tringale, K.; Hajj, C.; Moore, Z.; Hubbeling, H.; Dreyfuss, A.; Fregonese, B.; Falchi, L.; Scordo, M.; Grommes, C.; more...
Neuro-Oncology (2024)

Fulltext@MSK | Save